Aequus Pharmaceuticals Inc. announced that it has advanced the filings for provincial reimbursement in both Quebec and British Columbia for its lead product, Vistitan (bimatoprost 0.03%). If successful, this additional coverage would advance sales in the second and third largest markets in Canada and would trigger an increase in the percentage of total revenue that the company receives from its partner.